You can access information for this clinical trial in the links pdf.
Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithomycin combination, and in COVID-19 control patients.
Possible treatments for coronavirus:
Remdesivir by the firm Gilead was developed to fight other viruses including Ebola (where it was shown to be ineffective) and it hasn’t yet been approved for treating anything. Still, it has shown early promise in treating some coronavirus patients in China, according to doctors, and manufacturer Gilead is moving ahead with final stage clinical trials in Asia. It has also been used to treat at least one US patient so far.
NIH’s Anthony Fauci, one of the top government scientists overseeing the coronavirus response, has said it could be available in the next “several months.”
Continue reading “Over 20 vaccines, multiple treatments currently in development for coronavirus” »
If it wins FDA approval next year, the two-part sensor could help spot new infections weeks before symptoms begin to show.
Why are pandemics so hard to stop? Often it’s because the disease moves faster than people can be tested for it. The Defense Department is helping to fund a new study to determine whether an under-the-skin biosensor can help trackers keep up — by detecting flu-like infections even before their symptoms begin to show. Its maker, Profusa, says the sensor is on track to try for FDA approval by early next year.
The sensor has two parts. One is a 3mm string of hydrogel, a material whose network of polymer chains is used in some contact lenses and other implants. Inserted under the skin with a syringe, the string includes a specially engineered molecule that sends a fluorescent signal outside of the body when the body begins to fight an infection. The other part is an electronic component attached to the skin. It sends light through the skin, detects the fluorescent signal and generates another signal that the wearer can send to a doctor, website, etc. It’s like a blood lab on the skin that can pick up the body’s response to illness before the presence of other symptoms, like coughing.
The scientists running Seattle-based Oceans Initiative more typically apply their marine mammal expertise to research on endangered orcas or conservation of white-sided dolphins in Washington’s Puget Sound.
But the upside-down world of the new coronavirus and the closure of their nearly 6-year-old daughter’s school inspired them this week to launch what they’ve dubbed their Virtual Marine Biology Camp.
“We thought maybe it would be fun for a group of us to be able to hang out online and talk about whales and dolphins and other marine life,” said Erin Ashe, executive director and scientist with the nonprofit institute.
Restrictions are being eased across China as the number of new infections recorded drops sharply.
A study published in Aging and Disease shows the effectiveness of mesenchymal stem cell (MSC) therapy against a deadly immune reaction caused by COVID-19.
While scientists all over the world are working on a vaccine that would be effective against the SARS-CoV-2 coronavirus, which is responsible for the COVID-19 pandemic, a group of researchers from China and other countries has been exploring a therapeutic approach. Capitalizing on previous research, this group has conducted a successful trial of MSC therapy, resulting in the recovery of all seven patients [1]. These important results inspire hope, considering that a vaccine may still be more than a year away.
The decision by the L.A. County public health system not to test patients with coronavirus symptoms could make it difficult to know how many people are infected.
“The Justice Department has quietly asked Congress for the ability to ask chief judges to detain people indefinitely without trial during emergencies — part of a push for new powers that comes as the coronavirus spreads through the United States.”
One of the requests to Congress would allow the department to petition a judge to indefinitely detain someone during an emergency.
A sailor aboard a U.S. Navy ship has returned “presumptive positive” test results for coronavirus, in what is the first instance of a coronavirus case for a sailor aboard one of the service’s ships.
STAT1-deficient mice are more susceptible to infection with severe acute respiratory syndrome coronavirus (SARS-CoV) than type I interferon (IFN) receptor-deficient mice. We used mice lacking functional receptors for both type I and type III IFN (double knockout, dKO) to evaluate the possibility that type III IFN plays a decisive role in SARS-CoV protection. We found that viral peak titres in lungs of dKO and STAT1-deficient mice were similar, but significantly higher than in wild-type mice. The kinetics of viral clearance from the lung were also comparable in dKO and STAT1-deficient mice. Surprisingly, however, infected dKO mice remained healthy, whereas infected STAT1-deficient mice developed liver pathology and eventually succumbed to neurological disease. Our data suggest that the failure of STAT1-deficient mice to control initial SARS-CoV replication efficiently in the lung is due to impaired type I and type III IFN signalling, whereas the failure to control subsequent systemic viral spread is due to unrelated defects in STAT1-deficient mice.
